Supervisory Board

Prof Christof Hettich, LLD (Chairman)

Partner at RITTERSHAUS Lawyers
Vorstandsvorsitzender der SRH Holding SdbR

Professor Christof Hettich has been a member of the Supervisory Board since 21 May 2010, was re-elected on 22 July 2020 and is its current Chairman. Professor Hettich is a lawyer and partner at RITTERSHAUS Rechtsanwälte in Mannheim/Frankfurt/Munich. He studied law and political science at the Universities of Freiburg, Würzburg and Mannheim, obtaining his PhD from the University of Würzburg. Professor Hettich has extensive experience in arranging M&A transactions as well as in the structuring and restructuring of medium-sized and public companies. He manages the procurement of private equity financing including the preparation of share issues in sectors such as biotechnology and medical technology.

Dr Georg F. Baur (Deputy Chairman)

Entrepreneur

Dr Georg F. Baur was re-elected to the Supervisory Board on 22 July 2020 and is its current Deputy Chairman. He had already held this position from 28 August 2003 to 30 July 2015 after serving as the Supervisory Board’s chairman from 14 December 2000 to 28 August 2003. Dr Baur works as an entrepreneur in the areas of private investments and asset management. Between 1990 and 1992, he was Managing Partner of Lehndorff Vermögensverwaltungs GmbH. From 1979 to 1989, Dr Baur held various positions at JP Morgan, ultimately as Managing Director and Treasurer of the bank in London. He holds a PhD from the University of St. Gallen, Switzerland.

 

 

 

 

Dr Mathias Hothum (Deputy Chairman)

Managing Director of dievini Verwaltungs GmbH 

Dr Mathias Hothum was elected by the Annual General Meeting on 30 July 2015 and re-elected on 22 July 2020. Dr Hothum serves as Managing Director of dievini Verwaltungs GmbH, which in turn acts as the manager of dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, a company that supports and mentors SAP founder Dietmar Hopp in his investments in life sciences and advises the companies from the industry in which Mr Hopp invests on their corporate and business development. Since 1992, Dr Mathias Hothum is owner and managing director of HMM Consulting in Walldorf. With his expertise and experience of twenty years as a self-employed consultant in the area of health care he advised not only companies. He also shared his expertise with students as a lecture at the SRH Hochschule Heidelberg. Dr Hothum received his diplom degree in Economics from the University of Mannheim. He went on to do his PhD at the University of Magdeburg.

Dr Friedrich von Bohlen und Halbach

Managing Director of Moelcular Health GmbH 

Dr Friedrich von Bohlen und Halbach has been a member of the Supervisory Board since 29 April 2005 and was re-elected on 22 July 2020. Friedrich von Bohlen holds a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich. He held various positions at Fresenius AG, FAG Kugelfischer KGaA and WASAG Chemie AG. In 1997 he founded LION bioscience AG whose CEO he was for seven years. He is chairman of the Board of Apogenix AG and Novaliq GmbH, and board member of AC Immune SA, CureVac AG, immatics biotechnologies GmbH, Heidelberg Pharma AG and Co-Chair of the Evaluation Board of the Wyss Translational Center Zurich. Friedrich is also co-founder and managing director of Molecular Health GmbH.

 

 

Dr Birgit Kudlek

self-employed Pharmaceutical Manager

Dr Birgit Kudlek has been a member of the Supervisory Board since 25 May 2012 and was re-elected on 22 July 2020. Dr Kudlek has served as Chief Operating Officer and Chief Development Officer as well as Managing Director of AENOVA Holding GmbH in Starnberg. From 2009 to 2013, she was Head of the Sandoz Development Center Network at Sandoz International in Holzkirchen. From 2007 to 2008, she was an Executive Board Member of LTS Lohmann Therapie-Systeme, Andernach, where she was responsible for Technical Operations and Quality. From 2003 to 2007, Dr Kudlek worked for ratiopharm, Ulm, in various management positions within Technical Operations and Development, before taking over responsibility for global development activities. Prior to that Dr Kudlek was employed for more than four years as a consultant at Accenture, Kronberg. She started her career as Managing Assistant at Hoechst Marion Roussel, today Sanofi Aventis, Frankfurt. Birgit Kudlek studied Pharmaceutical Science as well as Economics and holds a PhD in Pharmaceutical Technology from the Technical University of Braunschweig.

Dr. Dongzhou Jeffery Liu, PhD

CSO and President of Huadong Global Development, Huadong Medicine Co., Ltd., Hangzhou, ChinaVerwaltungs GmbH 

Dr. Liu was elected by the Annual General Meeting on 28 June 2022. Since 2020, Dr. Liu is Chief Scientific Officer (CSO) at Huadong Medicine and President of Huadong Global Development in Hangzhou, China. Prior to that, he served as President R&D at Raynovent Biotechnology Co., Ltd, Guangzhou, China. From 2007 to 2019, he was Head of Clinical Development, Clinical Director and Medical Development Leader at GlaxoSmithKline (USA). Dr. Liu also worked at Wyeth (USA, now Pfizer, 1998-2003) and Forest Labs (USA, now Allergan, 2003-2007) with increasing responsibilities. His more than 20 years of industry experience include clinical and preclinical research & development of medicinal products. He contributed to several globally launched products. He obtained a PhD in Immunology/Biochemistry from Nankai University, Tianjin, China, a Master of Science in computer sciences from New York Long Island University, New York, USA, and a Bachelor of Science in Chemistry, Nankai University.

 

Dr. Brady Xumin Zhao, MD, PhD

Vice President, China Grand Enterprise, Inc., Beijing, China, controlling company of Huadong Medicine Co., Ltd., Hangzhou, China

Dr. Zhao was elected by the Annual General Meeting on 28 June 2022. Since 2021, Dr. Zhao is Vice President at China Grand Enterprise Inc. (CGE), located in Beijing, China. CGE is the controlling company of Huadong Medicine Co., Ltd. Prior to that, Dr. Zhao served as Head, Late Stage Oncology Clinical Development at Bayer from 2019 to 2021. From 2015 to 2019, he worked as Senior Director/Clinical Research Director at MSD. He held various positions in pharma companies, including Ferring, Pfizer, Bayer and Janssen. Before he started his career in industry, he worked as a physician at Beijing TongRen Hospital, Beijing, China. Dr. Zhao holds a PhD in medicine from Peking University, Beijing, China, and an MBA from Tsinghua University, Beijing, China.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.